Furthermore, increased ISG15 conjugation confers anti-cancer drug (e.g., Topotecan) sensitivity to tumors, validating the potential of ISG15 conjugates to serve as a biomarker for drug sensitivity in cancer patients [74]. The gene discussed is ISG15; the disease is cancer.